Summary
Ribometrix’s eIF4E inhibitors are novel, potent, selective inhibitors of cap-dependent translation initiation leading to anti-tumor activity in many cancer indications, including ER+ breast cancer. The combination of an eIF4E inhibitor with standard of care enhances response durability in ER+ breast cancer. eIF4E inhibitors have the potential to mitigate drug resistance and restore sensitivity to standard of care CDK4/6 inhibitors in the treatment resistant population.